Cart
sales@molnova.com
Trotabresib
CAS No. 1706738-98-8
Trotabresib( —— )
Catalog No. M34836 CAS No. 1706738-98-8
Trotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 128 | Get Quote |
|
| 5MG | 188 | Get Quote |
|
| 10MG | 312 | Get Quote |
|
| 25MG | 512 | Get Quote |
|
| 50MG | 731 | Get Quote |
|
| 100MG | 963 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTrotabresib
-
NoteResearch use only, not for human use.
-
Brief DescriptionTrotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.
-
DescriptionCC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1706738-98-8
-
Formula Weight383.46
-
Molecular FormulaC21H21NO4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (130.39 mM; Ultrasonic )
-
SMILESCn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. CELGENE QUANTICEL RESEARCH, INC. PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR. Patent. WO2020023438.
molnova catalog
related products
-
PBRM1-BD2-IN-7
PBRM1-BD2-IN-7, a selective and cell-active inhibitor targeting the polybromo-1 (PBRM1) bromodomain, demonstrates inhibitory efficacy against PBRM1-BD2 with an IC50 value of 0.29 μM.
-
BRD7-IN-1
BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), forms PROTAC VZ185 via linkage to a VHL ligand, demonstrating potent activity against BRD7/9 with DC50 values of 4.5 and 1.8 nM, respectively .
-
XD14
XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
